A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients With Advanced Solid Tumours Where the Androgen Receptor Pathway is a Potential Factor

Trial Profile

A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients With Advanced Solid Tumours Where the Androgen Receptor Pathway is a Potential Factor

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs IONIS AR 2.5Rx (Primary)
  • Indications Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Dec 2016 Results presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 13 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 12 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top